Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset of Type 1 Diabetes (NOT1D)

NCT07187531 is registered in ClinicalTrials.gov with SAb Biotherapeutics, Inc. as lead sponsor.

NCT NCT07187531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset of Type 1 Diabetes (NOT1D)
Lead sponsor
SAb Biotherapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2025
Completion date
December 31, 2028
Enrollment
159 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes